ORIGINAL ARTICLE

Thiol-producing microbiota of the intestine modulate oxidative stress and inflammation in Chronic Kidney Disease

Ika Nindya Kadariswantiningsih , Mochammad Thaha, Cahyo Wibisono Nugroho, Maulana Antiyan Empitu

Ika Nindya Kadariswantiningsih
Department of Medical Microbiology, Faculty of Medicine, Universitas Airlangga, Surabaya. Email: ika.nindya@fk.unair.ac.id

Mochammad Thaha
Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya Department of Internal Medicine, Universitas Airlangga Hospital, Surabaya

Cahyo Wibisono Nugroho
Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya Department of Internal Medicine, Universitas Airlangga Hospital, Surabaya

Maulana Antiyan Empitu
Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Airlangga, Surabaya
Online First: April 01, 2019 | Cite this Article
Kadariswantiningsih, I., Thaha, M., Nugroho, C., Empitu, M. 2019. Thiol-producing microbiota of the intestine modulate oxidative stress and inflammation in Chronic Kidney Disease. Bali Medical Journal 8(1): 307-311. DOI:10.15562/bmj.v8i1.1285


Background: Inflammation and oxidative stress are among the key contributing risk factors for cardiovascular disease (CVD) in chronic kidney disease (CKD). The human gut is the home for microbiota, of which some of the gram-negative gut bacteria are known to produce low-molecular-weight thiols including glutathione (GSH). GSH is used by mammals and eukaryotic cells as a substrate of glutathione peroxidase to eliminate reactive oxygen species. This study aims to investigate whether the presence of thiol-producing gut microbiota in CKD affects the level of oxidative stress and inflammation markers.

Methods: This study examined the stool sample of 41 CKD patients at three hospitals in Surabaya, Indonesia to identify the gram-negative bacteria producing thiols. Based on Ellman's assay result, the study participants were grouped into patients with thiol-producing and non-thiol-producing gram-negative gut microbiota. The markers of inflammation, high sensitivity C-reactive protein (hs-CRP), total antioxidant capacity (TAC), and urinary oxidative stress marker 8-hydroxy-2' -deoxyguanosine (8-OHdG) were compared between the two groups.

Results: The group with thiol-producing gut microbiota exhibited lower levels of plasma hs-CRP and urinary 8-OHdG compared to the group with non-thiol-producing gram-negative gut microbiota. In contrast, the group with thiol-producing gut microbiota has higher TAC compared to the group with non-thiol-producing gram-negative gut microbiota.

Conclusion: This study emphasized that the phenotypical diversity regarding the ability to produce low-molecular-weight thiols might modulate inflammation and oxidative stress as CVD risk factors in CKD.

References

Eckardt K-U, Coresh J, Devuyst O, Johnson RJ, Köttgen A, Levey AS, et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet. 2013;382(9887):158–69.

Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459–544.

Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. 2016;12(2):73.

Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. Jama. 2014;311(24):2518–31.

Eckardt K-U, Berns JS, Rocco M V, Kasiske BL. Definition and classification of CKD: the debate should be about patient prognosis—a position statement from KDOQI and KDIGO. Am J kidney Dis. 2009;53(6):915–20.

Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339–52.

O’Shaughnessy MM, Montez-Rath ME, Lafayette RA, Winkelmayer WC. Patient characteristics and outcomes by GN subtype in ESRD. Clin J Am Soc Nephrol. 2015;CJN-11261114.

Kendrick J, Chonchol MB. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Rev Nephrol. 2008;4(12):672.

Vaziri ND, Zhao Y-Y, Pahl M V. Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment. Nephrol Dial Transplant. 2015;31(5):737–46.

Wang F, Jiang H, Shi K, Ren YI, Zhang PAN, Cheng S. Gut bacterial translocation is associated with microinflammation in end‐stage renal disease patients. Nephrology. 2012;17(8):733–8.

Shi K, Wang F, Jiang H, Liu H, Wei M, Wang Z, et al. Gut bacterial translocation may aggravate microinflammation in hemodialysis patients. Dig Dis Sci. 2014;59(9):2109–17.

Newton GL, Rawat M, La Clair JJ, Jothivasan VK, Budiarto T, Hamilton CJ, et al. Bacillithiol is an antioxidant thiol produced in Bacilli. Nat Chem Biol. 2009;5(9):625.

Keddis MT, Amer H, Voskoboev N, Kremers WK, Rule AD, Lieske JC. Creatinine–Based and Cystatin C–Based GFR Estimating Equations and Their Non-GFR Determinants in Kidney Transplant Recipients. Clin J Am Soc Nephrol. 2016;11(9):1640–9.

Akerboom TPM, Sies H. [48] Assay of glutathione, glutathione disulfide, and glutathione mixed disulfides in biological samples. In: Methods in enzymology. Elsevier; 1981. p. 373–82.

Greenblum S, Carr R, Borenstein E. Extensive strain-level copy-number variation across human gut microbiome species. Cell. 2015;160(4):583–94.

Masip L, Veeravalli K, Georgiou G. The many faces of glutathione in bacteria. Antioxid Redox Signal. 2006;8(5–6):753–62.

Allocati N, Federici L, Masulli M, Di Ilio C. Glutathione transferases in bacteria. FEBS J. 2009;276(1):58–75.

Hamza SM, Dyck JRB. Systemic and renal oxidative stress in the pathogenesis of hypertension: modulation of long-term control of arterial blood pressure by resveratrol. Front Physiol. 2014;5:292.

Thaha M, Yusuf M, Empitu MA, Bakarman A, Tomino Y. Distribution of dimethylarginine-dimethylaminohydrolase-II (DDAH2) gene polymorphism in hemodialysis patients. Acta Med Indones. 2013;45(2):83–8.

Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, et al. Inflammation, immunity, and hypertension. Hypertension. 2011;57(2):132–40.

Jalal D, Chonchol M, Etgen T, Sander D. C-reactive protein as a predictor of cardiovascular events in elderly patients with chronic kidney disease. J Nephrol. 2012;25(5):719.

Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62(5):1524–38.

Thaha M, Empitu MA, Kadariswantiningsih IN, Nugroho CW, Hasanatuludhhiyah N, Rasyid H, et al. Anthropometry-based Body Fat Percentage Predicts High hs-CRP in Chronic Kidney Disease Patients. Indones Biomed J. 2018;10(2):184–91.


No Supplementary Material available for this article.
Article Views      : 0
PDF Downloads : 0